Mucocort AB has been granted a patent in Australia for its medical technology innovation. The company has successfully developed M045A, an innovative mucoadhesive "patch" for the treatment of oral aphthous ulcers.
The Swedish MedTech company Mucocort AB has been granted a patent in China for its innovative product/technology, which has previously been approved under the European Patent System (EPC). Mucocort develops a mucoadhesive "patch" for mouth ulcers (aphthous stomatitis), one of the most common oral mucosal diseases.
Mucocort AB has received approval to start a clinical trial for an intraoral patch (M045A) to treat aphthous stomatitis, a condition causing mouth ulcers. The patch aims for immediate pain relief and healing promotion. The trial will be conducted in collaboration with Oral Care AB and produced by Aurena Laboratories AB in Sweden.
Swedish MedTech company Mucocort plans to launch a mucosal self-absorbing patch for pain relief in people suffering from aphthous stomatitis (mouth ulcers). The interest in Mucocort patch technology has increased after the approval of a European patent. Further, the Mucocort AB minority stakeholder Aurena Laboratories steps up with additional capital and increases its ownership.
Mucocort AB is a Swedish company that has developed a unique self-absorbing pain relief patch for people suffering from recurrent mouth ulcers - aphthous stomatitis. The company has now signed a production agreement with medical technology company Aurena Laboratories AB, which also becomes a stakeholder in Mucocort.